#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=1 .
1-1	0-1	1	quantity	new	_	_
1-2	2-3	.	_	_	_	_

#Text=Introduction
2-1	4-16	Introduction	abstract	new	_	_

#Text=Oxidative stress was identified as a hallmark of almost all cardiovascular and neurodegenerative diseases .
3-1	17-26	Oxidative	abstract[3]	new[3]	coref	4-1[8_3]
3-2	27-33	stress	abstract[3]	new[3]	_	_
3-3	34-37	was	_	_	_	_
3-4	38-48	identified	_	_	_	_
3-5	49-51	as	_	_	_	_
3-6	52-53	a	_	_	_	_
3-7	54-62	hallmark	_	_	_	_
3-8	63-65	of	_	_	_	_
3-9	66-72	almost	abstract[4]|abstract[5]	new[4]|new[5]	coref|coref|coref|coref	10-47[0_4]|10-47[101_5]|10-47[0_4]|10-47[101_5]
3-10	73-76	all	abstract[4]|abstract[5]	new[4]|new[5]	_	_
3-11	77-91	cardiovascular	abstract[4]|abstract[5]	new[4]|new[5]	_	_
3-12	92-95	and	abstract[5]	new[5]	_	_
3-13	96-113	neurodegenerative	abstract[5]|abstract[6]	new[5]|new[6]	_	_
3-14	114-122	diseases	abstract[5]|abstract[6]	new[5]|new[6]	_	_
3-15	123-124	.	_	_	_	_

#Text=The term oxidative stress describes a condition that is either characterized by increased generation of reactive oxygen and nitrogen species ( RONS ) and/or dysregulated cellular antioxidant defense mechanisms ( e. g. , decreased expression of central antioxidant enzymes ) .
4-1	125-128	The	abstract[8]	giv[8]	coref	11-5[106_8]
4-2	129-133	term	abstract|abstract[8]	new|giv[8]	_	_
4-3	134-143	oxidative	abstract[8]	giv[8]	_	_
4-4	144-150	stress	abstract[8]	giv[8]	_	_
4-5	151-160	describes	_	_	_	_
4-6	161-162	a	abstract[9]	new[9]	_	_
4-7	163-172	condition	abstract[9]	new[9]	_	_
4-8	173-177	that	_	_	_	_
4-9	178-180	is	_	_	_	_
4-10	181-187	either	_	_	_	_
4-11	188-201	characterized	_	_	_	_
4-12	202-204	by	_	_	_	_
4-13	205-214	increased	time[10]	new[10]	coref	11-37[116_10]
4-14	215-225	generation	time[10]	new[10]	_	_
4-15	226-228	of	time[10]	new[10]	_	_
4-16	229-237	reactive	time[10]|substance[11]	new[10]|new[11]	ana	5-1[0_11]
4-17	238-244	oxygen	time[10]|substance[11]	new[10]|new[11]	_	_
4-18	245-248	and	time[10]	new[10]	_	_
4-19	249-257	nitrogen	time[10]|animal|animal[13]	new[10]|new|new[13]	coref|coref	7-3[46_13]|7-3[46_13]
4-20	258-265	species	time[10]|animal[13]	new[10]|new[13]	_	_
4-21	266-267	(	_	_	_	_
4-22	268-272	RONS	event	new	coref	6-1[31_0]
4-23	273-274	)	_	_	_	_
4-24	275-281	and/or	_	_	_	_
4-25	282-294	dysregulated	abstract[17]	new[17]	coref	7-15[48_17]
4-26	295-303	cellular	abstract[17]	new[17]	_	_
4-27	304-315	antioxidant	abstract|abstract[17]	new|new[17]	coref	4-38
4-28	316-323	defense	abstract|abstract[17]	new|new[17]	_	_
4-29	324-334	mechanisms	abstract[17]	new[17]	_	_
4-30	335-336	(	_	_	_	_
4-31	337-339	e.	_	_	_	_
4-32	340-342	g.	_	_	_	_
4-33	343-344	,	_	_	_	_
4-34	345-354	decreased	abstract[18]	new[18]	_	_
4-35	355-365	expression	abstract[18]	new[18]	_	_
4-36	366-368	of	abstract[18]	new[18]	_	_
4-37	369-376	central	abstract[18]|object[20]	new[18]|new[20]	_	_
4-38	377-388	antioxidant	abstract[18]|abstract|object[20]	new[18]|giv|new[20]	_	_
4-39	389-396	enzymes	abstract[18]|object[20]	new[18]|new[20]	_	_
4-40	397-398	)	_	_	_	_
4-41	399-400	.	_	_	_	_

#Text=This will ultimately cause that tissue , plasma or intercellular fluid run out of low molecular weight antioxidant compounds leading to detrimental alterations of cellular redox state .
5-1	401-405	This	substance	giv	_	_
5-2	406-410	will	_	_	_	_
5-3	411-421	ultimately	_	_	_	_
5-4	422-427	cause	_	_	_	_
5-5	428-432	that	object[22]	new[22]	_	_
5-6	433-439	tissue	object[22]	new[22]	_	_
5-7	440-441	,	_	_	_	_
5-8	442-448	plasma	substance	new	_	_
5-9	449-451	or	_	_	_	_
5-10	452-465	intercellular	substance[24]	new[24]	_	_
5-11	466-471	fluid	substance[24]	new[24]	_	_
5-12	472-475	run	_	_	_	_
5-13	476-479	out	_	_	_	_
5-14	480-482	of	_	_	_	_
5-15	483-486	low	substance[27]	new[27]	_	_
5-16	487-496	molecular	substance[27]	new[27]	_	_
5-17	497-503	weight	place|substance[27]	new|new[27]	_	_
5-18	504-515	antioxidant	person|substance[27]	new|new[27]	_	_
5-19	516-525	compounds	substance[27]	new[27]	_	_
5-20	526-533	leading	_	_	_	_
5-21	534-536	to	_	_	_	_
5-22	537-548	detrimental	abstract[28]	new[28]	_	_
5-23	549-560	alterations	abstract[28]	new[28]	_	_
5-24	561-563	of	abstract[28]	new[28]	_	_
5-25	564-572	cellular	abstract[28]|abstract[30]	new[28]|new[30]	ana	7-1[45_30]
5-26	573-578	redox	abstract[28]|person|abstract[30]	new[28]|new|new[30]	_	_
5-27	579-584	state	abstract[28]|abstract[30]	new[28]|new[30]	_	_
5-28	585-586	.	_	_	_	_

#Text=The most abundant biological RONS include superoxide radical , hydrogen peroxide , hydroxyl radical , carbon-centered peroxides and peroxyl radicals , nitric oxide radical ( NO∙ ) , nitrogen dioxide radial , peroxynitrite , and hypochlorite .
6-1	587-590	The	event[31]	giv[31]	coref	12-14[0_31]
6-2	591-595	most	event[31]	giv[31]	_	_
6-3	596-604	abundant	event[31]	giv[31]	_	_
6-4	605-615	biological	event[31]	giv[31]	_	_
6-5	616-620	RONS	event[31]	giv[31]	_	_
6-6	621-628	include	_	_	_	_
6-7	629-639	superoxide	substance	new	coref	9-2
6-8	640-647	radical	_	_	_	_
6-9	648-649	,	_	_	_	_
6-10	650-658	hydrogen	substance[33]	new[33]	_	_
6-11	659-667	peroxide	substance[33]	new[33]	_	_
6-12	668-669	,	_	_	_	_
6-13	670-678	hydroxyl	abstract	new	_	_
6-14	679-686	radical	_	_	_	_
6-15	687-688	,	_	_	_	_
6-16	689-704	carbon-centered	substance[35]	new[35]	_	_
6-17	705-714	peroxides	substance[35]	new[35]	_	_
6-18	715-718	and	_	_	_	_
6-19	719-726	peroxyl	organization|object[37]	new|new[37]	_	_
6-20	727-735	radicals	object[37]	new[37]	_	_
6-21	736-737	,	_	_	_	_
6-22	738-744	nitric	abstract	new	coref	8-1
6-23	745-750	oxide	abstract	new	coref	8-1[50_0]
6-24	751-758	radical	_	_	_	_
6-25	759-760	(	_	_	_	_
6-26	761-764	NO∙	person	new	_	_
6-27	765-766	)	_	_	_	_
6-28	767-768	,	_	_	_	_
6-29	769-777	nitrogen	substance[42]	new[42]	_	_
6-30	778-785	dioxide	abstract|substance[42]	new|new[42]	_	_
6-31	786-792	radial	substance[42]	new[42]	_	_
6-32	793-794	,	_	_	_	_
6-33	795-808	peroxynitrite	substance	new	_	_
6-34	809-810	,	_	_	_	_
6-35	811-814	and	_	_	_	_
6-36	815-827	hypochlorite	substance	new	_	_
6-37	828-829	.	_	_	_	_

#Text=Some of these species were reported to act as cellular messengers and participate in redox signaling mechanisms .
7-1	830-834	Some	abstract[45]	giv[45]	_	_
7-2	835-837	of	abstract[45]	giv[45]	_	_
7-3	838-843	these	abstract[45]|animal[46]	giv[45]|giv[46]	coref	11-22[112_46]
7-4	844-851	species	abstract[45]|animal[46]	giv[45]|giv[46]	_	_
7-5	852-856	were	_	_	_	_
7-6	857-865	reported	_	_	_	_
7-7	866-868	to	_	_	_	_
7-8	869-872	act	_	_	_	_
7-9	873-875	as	_	_	_	_
7-10	876-884	cellular	_	_	_	_
7-11	885-895	messengers	_	_	_	_
7-12	896-899	and	_	_	_	_
7-13	900-911	participate	_	_	_	_
7-14	912-914	in	_	_	_	_
7-15	915-920	redox	abstract[48]	giv[48]	coref	8-30[59_48]
7-16	921-930	signaling	abstract|abstract[48]	new|giv[48]	coref	11-8[108_0]
7-17	931-941	mechanisms	abstract[48]	giv[48]	_	_
7-18	942-943	.	_	_	_	_

#Text=Nitric oxide ( NO∙ ) for instance acts as an important vasodilator and inhibitor of platelet activation via formation of nitrosyl-iron enzyme complexes but also provides the basis for wide-spread signaling mechanisms by S-nitros(yl)ation of protein thiol groups as exemplified by suppression of apoptosis by S-nitros(yl)ation of caspases .
8-1	944-950	Nitric	abstract|abstract[50]	giv|giv[50]	appos|coref|appos|coref	8-4[0_50]|9-46|8-4[0_50]|9-46
8-2	951-956	oxide	abstract[50]	giv[50]	_	_
8-3	957-958	(	_	_	_	_
8-4	959-962	NO∙	abstract	giv	coref	9-46[83_0]
8-5	963-964	)	_	_	_	_
8-6	965-968	for	_	_	_	_
8-7	969-977	instance	abstract[52]	new[52]	_	_
8-8	978-982	acts	abstract[52]	new[52]	_	_
8-9	983-985	as	abstract[52]	new[52]	_	_
8-10	986-988	an	abstract[52]	new[52]	_	_
8-11	989-998	important	abstract[52]	new[52]	_	_
8-12	999-1010	vasodilator	abstract[52]	new[52]	_	_
8-13	1011-1014	and	abstract[52]	new[52]	_	_
8-14	1015-1024	inhibitor	abstract[52]	new[52]	_	_
8-15	1025-1027	of	abstract[52]	new[52]	_	_
8-16	1028-1036	platelet	abstract[52]|object|event[54]	new[52]|new|new[54]	_	_
8-17	1037-1047	activation	abstract[52]|event[54]	new[52]|new[54]	_	_
8-18	1048-1051	via	abstract[52]|event[54]	new[52]|new[54]	_	_
8-19	1052-1061	formation	abstract[52]|event[54]|abstract[55]	new[52]|new[54]|new[55]	coref	11-31[115_55]
8-20	1062-1064	of	abstract[52]|event[54]|abstract[55]	new[52]|new[54]|new[55]	_	_
8-21	1065-1078	nitrosyl-iron	abstract[52]|event[54]|abstract[55]|abstract[57]	new[52]|new[54]|new[55]|new[57]	_	_
8-22	1079-1085	enzyme	abstract[52]|event[54]|abstract[55]|substance|abstract[57]	new[52]|new[54]|new[55]|new|new[57]	_	_
8-23	1086-1095	complexes	abstract[52]|event[54]|abstract[55]|abstract[57]	new[52]|new[54]|new[55]|new[57]	_	_
8-24	1096-1099	but	_	_	_	_
8-25	1100-1104	also	_	_	_	_
8-26	1105-1113	provides	_	_	_	_
8-27	1114-1117	the	abstract[58]	new[58]	_	_
8-28	1118-1123	basis	abstract[58]	new[58]	_	_
8-29	1124-1127	for	abstract[58]	new[58]	_	_
8-30	1128-1139	wide-spread	abstract[58]|abstract[59]	new[58]|giv[59]	_	_
8-31	1140-1149	signaling	abstract[58]|abstract[59]	new[58]|giv[59]	_	_
8-32	1150-1160	mechanisms	abstract[58]|abstract[59]	new[58]|giv[59]	_	_
8-33	1161-1163	by	abstract[58]|abstract[59]	new[58]|giv[59]	_	_
8-34	1164-1181	S-nitros(yl)ation	abstract[58]|abstract[59]|substance[60]	new[58]|giv[59]|new[60]	_	_
8-35	1182-1184	of	abstract[58]|abstract[59]|substance[60]	new[58]|giv[59]|new[60]	_	_
8-36	1185-1192	protein	abstract[58]|abstract[59]|substance[60]|substance|abstract[63]	new[58]|giv[59]|new[60]|new|new[63]	_	_
8-37	1193-1198	thiol	abstract[58]|abstract[59]|substance[60]|organization|abstract[63]	new[58]|giv[59]|new[60]|new|new[63]	_	_
8-38	1199-1205	groups	abstract[58]|abstract[59]|substance[60]|abstract[63]	new[58]|giv[59]|new[60]|new[63]	_	_
8-39	1206-1208	as	_	_	_	_
8-40	1209-1220	exemplified	_	_	_	_
8-41	1221-1223	by	_	_	_	_
8-42	1224-1235	suppression	event[64]	new[64]	_	_
8-43	1236-1238	of	event[64]	new[64]	_	_
8-44	1239-1248	apoptosis	event[64]|event	new[64]|new	_	_
8-45	1249-1251	by	_	_	_	_
8-46	1252-1269	S-nitros(yl)ation	substance[66]	new[66]	_	_
8-47	1270-1272	of	substance[66]	new[66]	_	_
8-48	1273-1281	caspases	substance[66]|abstract	new[66]|new	_	_
8-49	1282-1283	.	_	_	_	_

#Text=The superoxide radical anion ( O2∙− ) can be formed from different sources such as xanthine oxidase , NADPH ( nicotinamide adenine dinucleotide phosphate ) oxidases , uncoupled NO synthases and the mitochondrial respiratory chain , and represent in many ways a direct antagonist of nitric oxide as shown by the famous experiment by Gryglewski et al. .
9-1	1284-1287	The	abstract[69]	new[69]	appos	9-6[0_69]
9-2	1288-1298	superoxide	substance|abstract[69]	giv|new[69]	coref	10-4
9-3	1299-1306	radical	abstract[69]	new[69]	_	_
9-4	1307-1312	anion	abstract[69]	new[69]	_	_
9-5	1313-1314	(	_	_	_	_
9-6	1315-1319	O2∙−	abstract	giv	_	_
9-7	1320-1321	)	_	_	_	_
9-8	1322-1325	can	_	_	_	_
9-9	1326-1328	be	_	_	_	_
9-10	1329-1335	formed	_	_	_	_
9-11	1336-1340	from	_	_	_	_
9-12	1341-1350	different	abstract[71]	new[71]	_	_
9-13	1351-1358	sources	abstract[71]	new[71]	_	_
9-14	1359-1363	such	abstract[71]	new[71]	_	_
9-15	1364-1366	as	abstract[71]	new[71]	_	_
9-16	1367-1375	xanthine	abstract[71]|abstract|substance[73]	new[71]|new|new[73]	_	_
9-17	1376-1383	oxidase	abstract[71]|substance[73]	new[71]|new[73]	_	_
9-18	1384-1385	,	abstract[71]	new[71]	_	_
9-19	1386-1391	NADPH	abstract[71]|substance	new[71]|new	_	_
9-20	1392-1393	(	abstract[71]	new[71]	_	_
9-21	1394-1406	nicotinamide	abstract[71]|substance	new[71]|new	_	_
9-22	1407-1414	adenine	abstract[71]|person[77]	new[71]|new[77]	_	_
9-23	1415-1427	dinucleotide	abstract[71]|place|person[77]	new[71]|new|new[77]	_	_
9-24	1428-1437	phosphate	abstract[71]|person[77]	new[71]|new[77]	_	_
9-25	1438-1439	)	abstract[71]	new[71]	_	_
9-26	1440-1448	oxidases	abstract[71]|abstract	new[71]|new	_	_
9-27	1449-1450	,	abstract[71]	new[71]	_	_
9-28	1451-1460	uncoupled	abstract[71]	new[71]	_	_
9-29	1461-1463	NO	abstract[71]|substance[79]	new[71]|new[79]	_	_
9-30	1464-1473	synthases	abstract[71]|substance[79]	new[71]|new[79]	_	_
9-31	1474-1477	and	abstract[71]	new[71]	_	_
9-32	1478-1481	the	abstract[71]|abstract[80]	new[71]|new[80]	_	_
9-33	1482-1495	mitochondrial	abstract[71]|abstract[80]	new[71]|new[80]	_	_
9-34	1496-1507	respiratory	abstract[71]|abstract[80]	new[71]|new[80]	_	_
9-35	1508-1513	chain	abstract[71]|abstract[80]	new[71]|new[80]	_	_
9-36	1514-1515	,	_	_	_	_
9-37	1516-1519	and	_	_	_	_
9-38	1520-1529	represent	_	_	_	_
9-39	1530-1532	in	_	_	_	_
9-40	1533-1537	many	_	_	_	_
9-41	1538-1542	ways	_	_	_	_
9-42	1543-1544	a	abstract[81]	new[81]	_	_
9-43	1545-1551	direct	abstract[81]	new[81]	_	_
9-44	1552-1562	antagonist	abstract[81]	new[81]	_	_
9-45	1563-1565	of	abstract[81]	new[81]	_	_
9-46	1566-1572	nitric	abstract[81]|abstract|substance[83]	new[81]|giv|giv[83]	_	_
9-47	1573-1578	oxide	abstract[81]|substance[83]	new[81]|giv[83]	_	_
9-48	1579-1581	as	_	_	_	_
9-49	1582-1587	shown	_	_	_	_
9-50	1588-1590	by	_	_	_	_
9-51	1591-1594	the	event[84]	new[84]	_	_
9-52	1595-1601	famous	event[84]	new[84]	_	_
9-53	1602-1612	experiment	event[84]	new[84]	_	_
9-54	1613-1615	by	event[84]	new[84]	_	_
9-55	1616-1626	Gryglewski	event[84]|person	new[84]|new	_	_
9-56	1627-1629	et	event[84]	new[84]	_	_
9-57	1630-1633	al.	event[84]	new[84]	_	_
9-58	1634-1635	.	_	_	_	_

#Text=The existence of superoxide dismutases ( mitochondrial MnSOD and cytosolic/extracellular Cu , Zn-SOD ) implies that superoxide may be harmful for the cell , which is supported by the fact that deficiency in MnSOD is lethal and deficiency in Cu , Zn-SOD renders mice susceptible to cardiovascular and neuronal complications .
10-1	1636-1639	The	abstract[86]	new[86]	_	_
10-2	1640-1649	existence	abstract[86]	new[86]	_	_
10-3	1650-1652	of	abstract[86]	new[86]	_	_
10-4	1653-1663	superoxide	abstract[86]|substance|abstract[88]	new[86]|giv|new[88]	appos|coref|appos|coref	10-7[89_88]|10-17|10-7[89_88]|10-17
10-5	1664-1674	dismutases	abstract[86]|abstract[88]	new[86]|new[88]	_	_
10-6	1675-1676	(	_	_	_	_
10-7	1677-1690	mitochondrial	abstract[89]	giv[89]	_	_
10-8	1691-1696	MnSOD	abstract[89]	giv[89]	_	_
10-9	1697-1700	and	abstract[89]	giv[89]	_	_
10-10	1701-1724	cytosolic/extracellular	abstract[89]	giv[89]	_	_
10-11	1725-1727	Cu	abstract[89]|person	giv[89]|new	coref	10-40
10-12	1728-1729	,	_	_	_	_
10-13	1730-1736	Zn-SOD	_	_	_	_
10-14	1737-1738	)	_	_	_	_
10-15	1739-1746	implies	_	_	_	_
10-16	1747-1751	that	_	_	_	_
10-17	1752-1762	superoxide	substance	giv	coref	13-13
10-18	1763-1766	may	_	_	_	_
10-19	1767-1769	be	_	_	_	_
10-20	1770-1777	harmful	_	_	_	_
10-21	1778-1781	for	_	_	_	_
10-22	1782-1785	the	place[92]	new[92]	coref	15-46[0_92]
10-23	1786-1790	cell	place[92]	new[92]	_	_
10-24	1791-1792	,	_	_	_	_
10-25	1793-1798	which	_	_	_	_
10-26	1799-1801	is	_	_	_	_
10-27	1802-1811	supported	_	_	_	_
10-28	1812-1814	by	_	_	_	_
10-29	1815-1818	the	abstract[93]	new[93]	_	_
10-30	1819-1823	fact	abstract[93]	new[93]	_	_
10-31	1824-1828	that	abstract[94]	new[94]	coref	10-38[0_94]
10-32	1829-1839	deficiency	abstract[94]	new[94]	_	_
10-33	1840-1842	in	abstract[94]	new[94]	_	_
10-34	1843-1848	MnSOD	abstract[94]|substance	new[94]|new	_	_
10-35	1849-1851	is	_	_	_	_
10-36	1852-1858	lethal	_	_	_	_
10-37	1859-1862	and	_	_	_	_
10-38	1863-1873	deficiency	abstract	giv	_	_
10-39	1874-1876	in	_	_	_	_
10-40	1877-1879	Cu	person	giv	_	_
10-41	1880-1881	,	_	_	_	_
10-42	1882-1888	Zn-SOD	abstract	new	_	_
10-43	1889-1896	renders	_	_	_	_
10-44	1897-1901	mice	animal[99]	new[99]	_	_
10-45	1902-1913	susceptible	animal[99]	new[99]	_	_
10-46	1914-1916	to	_	_	_	_
10-47	1917-1931	cardiovascular	abstract|abstract[101]	giv|giv[101]	_	_
10-48	1932-1935	and	abstract[101]	giv[101]	_	_
10-49	1936-1944	neuronal	abstract[101]|person	giv[101]|new	_	_
10-50	1945-1958	complications	abstract	new	_	_
10-51	1959-1960	.	_	_	_	_

#Text=Since the transition between oxidative stress and redox signaling is a thin line , the exact knowledge of the identity of formed species , the cellular and subcellular localization of their formation , as well as their time duration and concentration , are of high clinical and pharmacological importance .
11-1	1961-1966	Since	_	_	_	_
11-2	1967-1970	the	event[104]	new[104]	_	_
11-3	1971-1981	transition	event[104]	new[104]	_	_
11-4	1982-1989	between	event[104]	new[104]	_	_
11-5	1990-1999	oxidative	event[104]|abstract|abstract[106]	new[104]|new|giv[106]	coref|coref|coref|coref	14-14|14-15[0_106]|14-14|14-15[0_106]
11-6	2000-2006	stress	event[104]|abstract[106]	new[104]|giv[106]	_	_
11-7	2007-2010	and	event[104]	new[104]	_	_
11-8	2011-2016	redox	event[104]|abstract|abstract[108]	new[104]|new|giv[108]	_	_
11-9	2017-2026	signaling	event[104]|abstract[108]	new[104]|giv[108]	_	_
11-10	2027-2029	is	_	_	_	_
11-11	2030-2031	a	abstract[109]	new[109]	appos	11-15[110_109]
11-12	2032-2036	thin	abstract[109]	new[109]	_	_
11-13	2037-2041	line	abstract[109]	new[109]	_	_
11-14	2042-2043	,	_	_	_	_
11-15	2044-2047	the	abstract[110]	giv[110]	_	_
11-16	2048-2053	exact	abstract[110]	giv[110]	_	_
11-17	2054-2063	knowledge	abstract[110]	giv[110]	_	_
11-18	2064-2066	of	abstract[110]	giv[110]	_	_
11-19	2067-2070	the	abstract[110]|abstract[111]	giv[110]|new[111]	_	_
11-20	2071-2079	identity	abstract[110]|abstract[111]	giv[110]|new[111]	_	_
11-21	2080-2082	of	abstract[110]|abstract[111]	giv[110]|new[111]	_	_
11-22	2083-2089	formed	abstract[110]|abstract[111]|animal[112]	giv[110]|new[111]|giv[112]	_	_
11-23	2090-2097	species	abstract[110]|abstract[111]|animal[112]	giv[110]|new[111]|giv[112]	_	_
11-24	2098-2099	,	abstract[110]|abstract[111]|animal[112]	giv[110]|new[111]|giv[112]	_	_
11-25	2100-2103	the	abstract[110]|abstract[111]|animal[112]|abstract[114]	giv[110]|new[111]|giv[112]|new[114]	_	_
11-26	2104-2112	cellular	abstract[110]|abstract[111]|animal[112]|abstract|abstract[114]	giv[110]|new[111]|giv[112]|new|new[114]	_	_
11-27	2113-2116	and	abstract[110]|abstract[111]|animal[112]|abstract[114]	giv[110]|new[111]|giv[112]|new[114]	_	_
11-28	2117-2128	subcellular	abstract[110]|abstract[111]|animal[112]|abstract[114]	giv[110]|new[111]|giv[112]|new[114]	_	_
11-29	2129-2141	localization	abstract[110]|abstract[111]|animal[112]|abstract[114]	giv[110]|new[111]|giv[112]|new[114]	_	_
11-30	2142-2144	of	abstract[110]|abstract[111]|animal[112]|abstract[114]	giv[110]|new[111]|giv[112]|new[114]	_	_
11-31	2145-2150	their	abstract[110]|abstract[111]|animal[112]|abstract[114]|abstract[115]	giv[110]|new[111]|giv[112]|new[114]|giv[115]	coref	13-12[134_115]
11-32	2151-2160	formation	abstract[110]|abstract[111]|animal[112]|abstract[114]|abstract[115]	giv[110]|new[111]|giv[112]|new[114]|giv[115]	_	_
11-33	2161-2162	,	abstract[110]|abstract[111]|animal[112]	giv[110]|new[111]|giv[112]	_	_
11-34	2163-2165	as	abstract[110]|abstract[111]|animal[112]	giv[110]|new[111]|giv[112]	_	_
11-35	2166-2170	well	abstract[110]|abstract[111]|animal[112]	giv[110]|new[111]|giv[112]	_	_
11-36	2171-2173	as	abstract[110]|abstract[111]|animal[112]	giv[110]|new[111]|giv[112]	_	_
11-37	2174-2179	their	abstract[110]|abstract[111]|animal[112]|time[116]|time[117]	giv[110]|new[111]|giv[112]|giv[116]|new[117]	_	_
11-38	2180-2184	time	abstract[110]|abstract[111]|animal[112]|time[116]|time[117]	giv[110]|new[111]|giv[112]|giv[116]|new[117]	_	_
11-39	2185-2193	duration	abstract[110]|abstract[111]|animal[112]|time[117]	giv[110]|new[111]|giv[112]|new[117]	_	_
11-40	2194-2197	and	abstract[110]|abstract[111]|animal[112]	giv[110]|new[111]|giv[112]	_	_
11-41	2198-2211	concentration	abstract[110]|abstract[111]|animal[112]|abstract	giv[110]|new[111]|giv[112]|new	_	_
11-42	2212-2213	,	abstract[110]|abstract[111]|animal[112]	giv[110]|new[111]|giv[112]	_	_
11-43	2214-2217	are	abstract[110]|abstract[111]|animal[112]	giv[110]|new[111]|giv[112]	_	_
11-44	2218-2220	of	abstract[110]|abstract[111]|animal[112]	giv[110]|new[111]|giv[112]	_	_
11-45	2221-2225	high	abstract[110]|abstract[111]|animal[112]|abstract[119]	giv[110]|new[111]|giv[112]|new[119]	_	_
11-46	2226-2234	clinical	abstract[110]|abstract[111]|animal[112]|abstract[119]	giv[110]|new[111]|giv[112]|new[119]	_	_
11-47	2235-2238	and	abstract[110]|abstract[111]|animal[112]|abstract[119]	giv[110]|new[111]|giv[112]|new[119]	_	_
11-48	2239-2254	pharmacological	abstract[110]|abstract[111]|animal[112]|abstract[119]	giv[110]|new[111]|giv[112]|new[119]	_	_
11-49	2255-2265	importance	abstract[110]|abstract[111]|animal[112]|abstract[119]	giv[110]|new[111]|giv[112]|new[119]	_	_
11-50	2266-2267	.	_	_	_	_

#Text=With our previous work , we have stressed that the traditional or old RONS assays are not necessarily inferior as compared to up-to-date or even cutting-edge assays and at least have their specific features and application spectra .
12-1	2268-2272	With	_	_	_	_
12-2	2273-2276	our	person|abstract[121]	acc|new[121]	ana|ana	12-6|12-6
12-3	2277-2285	previous	abstract[121]	new[121]	_	_
12-4	2286-2290	work	abstract[121]	new[121]	_	_
12-5	2291-2292	,	_	_	_	_
12-6	2293-2295	we	person	giv	ana	13-6
12-7	2296-2300	have	_	_	_	_
12-8	2301-2309	stressed	_	_	_	_
12-9	2310-2314	that	_	_	_	_
12-10	2315-2318	the	abstract[124]	new[124]	coref	12-23[125_124]
12-11	2319-2330	traditional	abstract[124]	new[124]	_	_
12-12	2331-2333	or	abstract[124]	new[124]	_	_
12-13	2334-2337	old	abstract[124]	new[124]	_	_
12-14	2338-2342	RONS	event|abstract[124]	giv|new[124]	_	_
12-15	2343-2349	assays	abstract[124]	new[124]	_	_
12-16	2350-2353	are	_	_	_	_
12-17	2354-2357	not	_	_	_	_
12-18	2358-2369	necessarily	_	_	_	_
12-19	2370-2378	inferior	_	_	_	_
12-20	2379-2381	as	_	_	_	_
12-21	2382-2390	compared	_	_	_	_
12-22	2391-2393	to	_	_	_	_
12-23	2394-2404	up-to-date	abstract[125]	giv[125]	ana	12-32[0_125]
12-24	2405-2407	or	abstract[125]	giv[125]	_	_
12-25	2408-2412	even	abstract[125]	giv[125]	_	_
12-26	2413-2425	cutting-edge	abstract[125]	giv[125]	_	_
12-27	2426-2432	assays	abstract[125]	giv[125]	_	_
12-28	2433-2436	and	_	_	_	_
12-29	2437-2439	at	_	_	_	_
12-30	2440-2445	least	_	_	_	_
12-31	2446-2450	have	_	_	_	_
12-32	2451-2456	their	abstract|abstract[127]	giv|new[127]	_	_
12-33	2457-2465	specific	abstract[127]	new[127]	_	_
12-34	2466-2474	features	abstract[127]	new[127]	_	_
12-35	2475-2478	and	_	_	_	_
12-36	2479-2490	application	abstract|abstract[129]	new|new[129]	_	_
12-37	2491-2498	spectra	abstract[129]	new[129]	_	_
12-38	2499-2500	.	_	_	_	_

#Text=With the present studies , we evaluated the specific probe for mitochondrial superoxide formation , mitochondria-targeted , triphenylphosphonium-linked hydroethidium ( mitoSOX ) , for its usefulness in the detection of mitochondrial superoxide formation ex vivo/in vivo and compared this high-performance/pressure liquid chromatography ( HPLC)-based assay with two alternative/traditional methods .
13-1	2501-2505	With	_	_	_	_
13-2	2506-2509	the	abstract[130]	new[130]	_	_
13-3	2510-2517	present	abstract[130]	new[130]	_	_
13-4	2518-2525	studies	abstract[130]	new[130]	_	_
13-5	2526-2527	,	_	_	_	_
13-6	2528-2530	we	person	giv	ana	14-5
13-7	2531-2540	evaluated	_	_	_	_
13-8	2541-2544	the	event[132]	new[132]	_	_
13-9	2545-2553	specific	event[132]	new[132]	_	_
13-10	2554-2559	probe	event[132]	new[132]	_	_
13-11	2560-2563	for	event[132]	new[132]	_	_
13-12	2564-2577	mitochondrial	event[132]|abstract[134]	new[132]|giv[134]	coref	13-31[141_134]
13-13	2578-2588	superoxide	event[132]|substance|abstract[134]	new[132]|giv|giv[134]	coref	13-32
13-14	2589-2598	formation	event[132]|abstract[134]	new[132]|giv[134]	_	_
13-15	2599-2600	,	event[132]	new[132]	_	_
13-16	2601-2622	mitochondria-targeted	event[132]	new[132]	_	_
13-17	2623-2624	,	event[132]	new[132]	_	_
13-18	2625-2652	triphenylphosphonium-linked	event[132]|substance[135]	new[132]|new[135]	ana	13-25[0_135]
13-19	2653-2666	hydroethidium	event[132]|substance[135]	new[132]|new[135]	_	_
13-20	2667-2668	(	event[132]	new[132]	_	_
13-21	2669-2676	mitoSOX	event[132]|object	new[132]|new	_	_
13-22	2677-2678	)	event[132]	new[132]	_	_
13-23	2679-2680	,	event[132]	new[132]	_	_
13-24	2681-2684	for	event[132]	new[132]	_	_
13-25	2685-2688	its	event[132]|substance|abstract[138]	new[132]|giv|new[138]	_	_
13-26	2689-2699	usefulness	event[132]|abstract[138]	new[132]|new[138]	_	_
13-27	2700-2702	in	event[132]|abstract[138]	new[132]|new[138]	_	_
13-28	2703-2706	the	event[132]|abstract[138]|abstract[139]	new[132]|new[138]|new[139]	coref	15-19[161_139]
13-29	2707-2716	detection	event[132]|abstract[138]|abstract[139]	new[132]|new[138]|new[139]	_	_
13-30	2717-2719	of	event[132]|abstract[138]|abstract[139]	new[132]|new[138]|new[139]	_	_
13-31	2720-2733	mitochondrial	event[132]|abstract[138]|abstract[139]|abstract[141]	new[132]|new[138]|new[139]|giv[141]	_	_
13-32	2734-2744	superoxide	event[132]|abstract[138]|abstract[139]|substance|abstract[141]	new[132]|new[138]|new[139]|giv|giv[141]	coref	15-19
13-33	2745-2754	formation	event[132]|abstract[138]|abstract[139]|abstract[141]	new[132]|new[138]|new[139]|giv[141]	_	_
13-34	2755-2757	ex	_	_	_	_
13-35	2758-2765	vivo/in	_	_	_	_
13-36	2766-2770	vivo	_	_	_	_
13-37	2771-2774	and	_	_	_	_
13-38	2775-2783	compared	_	_	_	_
13-39	2784-2788	this	object[143]	new[143]	_	_
13-40	2789-2814	high-performance/pressure	object[143]	new[143]	_	_
13-41	2815-2821	liquid	substance|object[143]	new|new[143]	_	_
13-42	2822-2836	chromatography	object[143]	new[143]	_	_
13-43	2837-2838	(	_	_	_	_
13-44	2839-2850	HPLC)-based	abstract[144]	new[144]	_	_
13-45	2851-2856	assay	abstract[144]	new[144]	_	_
13-46	2857-2861	with	abstract[144]	new[144]	_	_
13-47	2862-2865	two	abstract[144]|abstract[145]	new[144]|new[145]	_	_
13-48	2866-2889	alternative/traditional	abstract[144]|abstract[145]	new[144]|new[145]	_	_
13-49	2890-2897	methods	abstract[144]|abstract[145]	new[144]|new[145]	_	_
13-50	2898-2899	.	_	_	_	_

#Text=For this purpose , we used three different animal models with well established oxidative stress burden , namely diabetic , hypertensive and nitrate tolerant rats .
14-1	2900-2903	For	_	_	_	_
14-2	2904-2908	this	abstract[146]	new[146]	_	_
14-3	2909-2916	purpose	abstract[146]	new[146]	_	_
14-4	2917-2918	,	_	_	_	_
14-5	2919-2921	we	person	giv	ana	15-25
14-6	2922-2926	used	_	_	_	_
14-7	2927-2932	three	abstract[149]	new[149]	_	_
14-8	2933-2942	different	abstract[149]	new[149]	_	_
14-9	2943-2949	animal	animal|abstract[149]	new|new[149]	_	_
14-10	2950-2956	models	abstract[149]	new[149]	_	_
14-11	2957-2961	with	abstract[149]	new[149]	_	_
14-12	2962-2966	well	abstract[149]|abstract[152]	new[149]|new[152]	_	_
14-13	2967-2978	established	abstract[149]|abstract[152]	new[149]|new[152]	_	_
14-14	2979-2988	oxidative	abstract[149]|abstract|abstract[152]	new[149]|giv|new[152]	_	_
14-15	2989-2995	stress	abstract[149]|abstract|abstract[152]	new[149]|giv|new[152]	_	_
14-16	2996-3002	burden	abstract[149]|abstract[152]	new[149]|new[152]	_	_
14-17	3003-3004	,	_	_	_	_
14-18	3005-3011	namely	animal[153]	new[153]	_	_
14-19	3012-3020	diabetic	animal[153]	new[153]	_	_
14-20	3021-3022	,	animal[153]	new[153]	_	_
14-21	3023-3035	hypertensive	animal[153]	new[153]	_	_
14-22	3036-3039	and	animal[153]	new[153]	_	_
14-23	3040-3047	nitrate	animal[153]	new[153]	_	_
14-24	3048-3056	tolerant	animal[153]	new[153]	_	_
14-25	3057-3061	rats	animal[153]	new[153]	_	_
14-26	3062-3063	.	_	_	_	_

#Text=Given the recent report by Xiao & Meierhofer raising doubts about the reliable use of hydroethidium-based probes for superoxide detection in cell culture , we think that our present data are of interest for all researchers using hydroethidium-based probes , but especially mitoSOX , in cell culture , isolated mitochondria and tissue samples .
15-1	3064-3069	Given	_	_	_	_
15-2	3070-3073	the	abstract[154]	new[154]	_	_
15-3	3074-3080	recent	abstract[154]	new[154]	_	_
15-4	3081-3087	report	abstract[154]	new[154]	_	_
15-5	3088-3090	by	abstract[154]	new[154]	_	_
15-6	3091-3095	Xiao	abstract[154]|person	new[154]|new	_	_
15-7	3096-3097	&	abstract[154]|person[156]	new[154]|new[156]	_	_
15-8	3098-3108	Meierhofer	abstract[154]|person[156]	new[154]|new[156]	_	_
15-9	3109-3116	raising	_	_	_	_
15-10	3117-3123	doubts	abstract[157]	new[157]	_	_
15-11	3124-3129	about	abstract[157]	new[157]	_	_
15-12	3130-3133	the	abstract[157]|event[158]	new[157]|new[158]	_	_
15-13	3134-3142	reliable	abstract[157]|event[158]	new[157]|new[158]	_	_
15-14	3143-3146	use	abstract[157]|event[158]	new[157]|new[158]	_	_
15-15	3147-3149	of	abstract[157]|event[158]	new[157]|new[158]	_	_
15-16	3150-3169	hydroethidium-based	abstract[157]|event[158]|event[159]	new[157]|new[158]|new[159]	coref	15-38[167_159]
15-17	3170-3176	probes	abstract[157]|event[158]|event[159]	new[157]|new[158]|new[159]	_	_
15-18	3177-3180	for	abstract[157]|event[158]|event[159]	new[157]|new[158]|new[159]	_	_
15-19	3181-3191	superoxide	abstract[157]|event[158]|event[159]|person|abstract[161]	new[157]|new[158]|new[159]|giv|giv[161]	_	_
15-20	3192-3201	detection	abstract[157]|event[158]|event[159]|abstract[161]	new[157]|new[158]|new[159]|giv[161]	_	_
15-21	3202-3204	in	abstract[157]|event[158]|event[159]|abstract[161]	new[157]|new[158]|new[159]|giv[161]	_	_
15-22	3205-3209	cell	abstract[157]|event[158]|event[159]|abstract[161]|abstract[162]	new[157]|new[158]|new[159]|giv[161]|new[162]	coref	15-46[169_162]
15-23	3210-3217	culture	abstract[157]|event[158]|event[159]|abstract[161]|abstract[162]	new[157]|new[158]|new[159]|giv[161]|new[162]	_	_
15-24	3218-3219	,	_	_	_	_
15-25	3220-3222	we	person	giv	ana	15-28
15-26	3223-3228	think	_	_	_	_
15-27	3229-3233	that	_	_	_	_
15-28	3234-3237	our	person|abstract[165]	giv|new[165]	_	_
15-29	3238-3245	present	abstract[165]	new[165]	_	_
15-30	3246-3250	data	abstract[165]	new[165]	_	_
15-31	3251-3254	are	_	_	_	_
15-32	3255-3257	of	_	_	_	_
15-33	3258-3266	interest	_	_	_	_
15-34	3267-3270	for	_	_	_	_
15-35	3271-3274	all	person[166]	new[166]	_	_
15-36	3275-3286	researchers	person[166]	new[166]	_	_
15-37	3287-3292	using	_	_	_	_
15-38	3293-3312	hydroethidium-based	event[167]	giv[167]	_	_
15-39	3313-3319	probes	event[167]	giv[167]	_	_
15-40	3320-3321	,	_	_	_	_
15-41	3322-3325	but	_	_	_	_
15-42	3326-3336	especially	_	_	_	_
15-43	3337-3344	mitoSOX	_	_	_	_
15-44	3345-3346	,	_	_	_	_
15-45	3347-3349	in	_	_	_	_
15-46	3350-3354	cell	place|abstract[169]	giv|giv[169]	_	_
15-47	3355-3362	culture	abstract[169]	giv[169]	_	_
15-48	3363-3364	,	_	_	_	_
15-49	3365-3373	isolated	animal[170]	new[170]	_	_
15-50	3374-3386	mitochondria	animal[170]	new[170]	_	_
15-51	3387-3390	and	_	_	_	_
15-52	3391-3397	tissue	object[171]	new[171]	_	_
15-53	3398-3405	samples	object[171]	new[171]	_	_
15-54	3406-3407	.	_	_	_	_
